Everest Medicines Completes HK$1.57 Billion Share Placement to Advance R&D and Commercialization
China-based Everest Medicines (HKG: 1952) announced today the completion of a share placement of 22,561,000...
Yangtze River Pharmaceutical’s Tadalafil Hydrochloride Tablets Approved for ED Treatment in China
China-based Yangtze River Pharmaceutical Group announced on July 25, 2025, that its Class 1 innovative...
Ipsen’s Cabometyx Approved by European Commission for Neuroendocrine Tumors
France-based pharmaceutical company Ipsen S.A. (EPA: IPN, OTCMKTS: IPSEY) announced that its anticancer drug Cabometyx...
NHSA Announces Reforms to Centralized Drug Procurement Policies Beyond Lowest Price
The National Healthcare Security Administration (NHSA) held a press conference today on the “High-Quality Completion...
Boehringer Ingelheim Reports 6.3% Sales Growth in First Half of 2025
Boehringer Ingelheim announced today its financial results for the first half of 2025, reporting group...
Kelun-Biotech’s SKB378/WIN378 Enters Global Phase II Trial for Asthma Treatment
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (HKG: 6990) announced on July 23, 2025, that its partner...
Sirius Therapeutics’ SRSD107 Receives EMA Approval for Phase II Clinical Trials in Thromboembolic Diseases
China-based Sirius Therapeutics announced on July 23, 2025, that its next-generation siRNA therapy, SRSD107, has...
Akeso Enrolls First Patient in Phase III Trial of Ivonescimab for Pancreatic Cancer
China-based Akeso Biopharma (HKG: 9926) announced on July 24, 2025, that the first patient has...
Youcare Pharma’s YKYY029 Receives FDA IND Approval for Hypertension Treatment
China-based Youcare Pharmaceutical Group (SHA: 688658) announced on July 24, 2025, that its subsidiary, Beijing...
National Health Commission Launches Integrated Medical and Elder Care Demonstration Projects
On July 22, 2025, China’s National Health Commission (NHC) issued the “Work Plan for Integrated...
Kintor’s KX-826 Topical Solution Meets Primary Endpoint in AGA Phase II Trial
China-based Kintor Pharmaceutical (HKG: 9939) announced on July 24, 2025, that its self-developed 1.0% KX-826...
Ascentage Pharma Collaborates with Major Chinese Firms to Commercialize Lisaftoclax
China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) announced today that it has entered into cooperation...
Shanghai Kehua Bioengineering Subsidiary Receives Two IVD Certificates from NMPA
China-based Shanghai Kehua Bioengineering Co., Ltd. (KHB) (SHE: 002022) announced on July 23, 2025, that...
Shenzhen Beimei’s TWYNEO Receives NMPA Clinical Trial Approval for Acne Treatment
Shenzhen Beimei Pharmaceutical Co., Ltd. announced on July 22, 2025, that its drug TWYNEO (tretinoin...
Chison Medical and Gates Foundation Collaborate on Innovative Ultrasound Equipment
China-based Chison Medical Technologies (SHA: 688358) announced on July 23, 2025, a partnership with the...
Shanghai MicroPort EP MedTech’s IceMagic Catheter Receives EU MDR Certification
Shanghai-based Shanghai MicroPort EP MedTech Co., Ltd. (SHA: 688351) announced on July 23, 2025, that...
CTTQ Doses First Patient in China for TQB6411 Phase I Clinical Trial
Subsidiary of China based Sino Biopharmaceutical Ltd (HKG: 1177) Jiangsu Chia Tai Tianqing Pharmaceutical Co.,...
FDA-Approved Smile System Launches in Lecheng for ADHD Treatment
On July 22, 2025, the innovative non-pharmacological ADHD treatment medical device “Smile” (ADHD Transcutaneous Nerve...
Grand Pharma’s TLX591 Granted NMPA Approval for Phase III Prostate Cancer Trial
China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced that its innovative radiolabeled drug conjugate (RDC)...
Abbisko Therapeutics Completes First Patient Dosing for PRMT5×MTA Inhibitor ABSK131
Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) announced the completion of the first patient...